Загрузка...
A 6-month mixed-effect pharmacokinetic model for post-transplant intravenous anti-hepatitis B immunoglobulin prophylaxis
BACKGROUND: Although individualized dosage regimens for anti-hepatitis B immunoglobulin (HBIG) therapy have been suggested, the pharmacokinetic profile and factors influencing the basis for individualization have not been sufficiently assessed. We sought to evaluate the pharmacokinetic characteristi...
Сохранить в:
| Опубликовано в: : | Drug Des Devel Ther |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5513836/ https://ncbi.nlm.nih.gov/pubmed/28744101 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S134711 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|